Perfusion MRI After Donepezil in Lewy Body Dementia

多奈哌齐治疗路易体痴呆后的灌注 MRI

• 批准号: 7002727
• 负责人: TAMARA G FONG
• 金额: $ 5.75万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7002727
• 关键词: Lewy body; bioimaging /biomedical imaging; biomarker; brain disorder chemotherapy; cerebrovascular imaging /visualization; cholinesterase inhibitors; clinical research; clinical trials; cognition; dementia; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; longitudinal human study; magnetic resonance imaging; neuropathology; neuropharmacologic agent; neuropharmacology; neuropsychological tests; outcomes research; patient oriented research; perfusion; pharmacokinetics; postdoctoral investigator

DESCRIPTION (provided by applicant): A major limitation in the development of effective treatment for dementia has been poor understanding of the relationship between neuronal transmission and behavior. This study will use arterial spin labeled perfusion MRI (ASL-pMRI) to measure changes in regional cerebral blood flow (rCBF) following acute and chronic administration of cholinesterase inhibitors (ChEI) in diffuse Lewy body dementia. Simultaneous high resolution structural imaging and contemporary neuropsychological assessments will be obtained. From this a relationship between cognitive performance and changes in rCBF can be defined. Additionally, combined structural and perfusion MRI will provide information that may predict clinical response to ChEI. The trial will include two phases, first, a double-blind, randomized, crossover, placebo-controlled trial to measure the effects of a single oral dose of ChEI on cognitive function and rCBF. The second phase will be an open labeled, prospective study to assess the chronic effects of ChEI administered over a period of three months.

描述(由申请人提供)： 发展有效的痴呆症治疗方法的一个主要限制因素是对神经元传递和行为之间的关系缺乏了解。这项研究将使用动脉自旋标记灌注磁共振成像(ASL-pMRI)来测量弥漫性路易体痴呆患者急性和慢性应用胆碱酯酶抑制剂(ChEI)后局部脑血流量(RCBF)的变化。将同时进行高分辨率结构成像和当代神经心理学评估。由此可以确定认知表现和局部脑血流量变化之间的关系。此外，结合结构和灌注MRI将提供可能预测CHEI临床反应的信息。该试验将包括两个阶段，第一，双盲、随机、交叉、安慰剂对照试验，以衡量单剂量口服CHEI对认知功能和rCBF的影响。第二阶段将是一项开放标记的前瞻性研究，以评估在三个月内应用CHEI的慢性影响。